40M.F NANEXA AB

Healthcare Pharmaceuticals Frankfurt Exchange
0.8780 EUR
Close of Nov 11, 2026
0.1264 1.28
Market cap
EUR 168M
P/E
12.5x
P/B
5.92x
ROE
56.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 40M.F undervalued?

Graham number
Price0.8780
Graham value0.4833
Premium81.7%

40M.F trades 81.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NANEXA AB fundamental analysis

No fundamental analysis for NANEXA AB yet.

NANEXA AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NANEXA AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a drug f…

Full company profile